Reply to "Uveal melanoma cells are resistant to EZH2 inhibition regardless of BAP1 status"
Nature Medicine2016Vol. 22(6), pp. 578–579
Citations Over TimeTop 13% of 2016 papers
Lindsay M. LaFave, Wendy Béguelin, Richard P. Koche, Matt Teater, Barbara Spitzer, Alan Chramiec, Efthymia Papalexi, Matthew D. Keller, Todd Hricik, Katerina Konstantinoff, Jean‐Baptiste Micol, Benjamin H. Durham, Sarah K. Knutson, John E. Campbell, Gil Blum, Xinxu Shi, Emma H. Doud, Andrei V. Krivtsov, Young Rock Chung, Inna Khodos, Elisa de Stanchina, Ouathek Ouerfelli, Prasad S. Adusumilli, Paul M. Thomas, Neil L. Kelleher, Minkui Luo, Heike Keilhack, Omar Abdel‐Wahab, Ari Melnick, Scott A. Armstrong, Ross L. Levine
Related Papers
- → The epigenetic modifier EZH2 controls melanoma growth and metastasis through silencing of distinct tumour suppressors(2015)331 cited
- → BAP1 deficiency causes loss of melanocytic cell identity in uveal melanoma(2013)153 cited
- → BAP1 Has a Survival Role in Cutaneous Melanoma(2014)37 cited
- → Multi-omics Profiling Shows BAP1 Loss Is Associated with Upregulated Cell Adhesion Molecules in Uveal Melanoma(2022)29 cited
- → The tumor suppressor BAP1 cooperates with BRAFV600E to promote tumor formation in cutaneous melanoma(2018)12 cited